Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line

Exploring mechanisms of drug resistance to targeted small molecule drugs is critical for an extended clinical benefit in the treatment of non-small cell lung cancer (NSCLC) patients carrying activating epidermal growth factor receptor (EGFR) mutations. Here, we identified constitutive cell prolifera...

Descripción completa

Detalles Bibliográficos
Autores principales: Saafan, Hisham, Alahdab, Ahmad, Michelet, Robin, Gohlke, Linus, Ziemann, Janine, Holdenrieder, Stefan, McLaughlin, Katie-May, Wass, Mark N., Cinatl, Jindrich, Michaelis, Martin, Kloft, Charlotte, Ritter, Christoph A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103245/
https://www.ncbi.nlm.nih.gov/pubmed/33804833
http://dx.doi.org/10.3390/cells10040716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103245/
https://www.ncbi.nlm.nih.gov/pubmed/33804833
http://dx.doi.org/10.3390/cells10040716

Ejemplares similares